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Butyrate and propionate inhibit 
antigen-specific CD8+ T cell 
activation by suppressing IL-12 
production by antigen-presenting 
cells
Claudia Nastasi1, Simon Fredholm1, Andreas Willerslev-Olsen1, Morten Hansen2,  
Charlotte Menné Bonefeld1, Carsten Geisler1, Mads Hald Andersen1,2, Niels Ødum  1 & 
Anders Woetmann  1
Short chain fatty acids (SCFAs), such as acetate, butyrate and propionate, are products of microbial 
macronutrients fermentation that distribute systemically and are believed to modulate host immune 
responses. Recent data have indicated that certain SCFAs, such as butyrate and propionate, directly 
modulate human dendritic cell (DC) function. Given the role of DCs in initiating and shaping the adaptive 
immune response, we now explore how SCFAs affect the activation of antigen-specific CD8+ T cells 
stimulated with autologous, MART1 peptide-pulsed DC. We show that butyrate reduces the frequency 
of peptide-specific CD8+ T cells and, together with propionate, inhibit the activity of those cells. On the 
contrary, acetate does not affect them. Importantly, butyrate and propionate inhibit the production 
of IL-12 and IL-23 in the DCs and exogenous IL-12 fully restores the activation of the MART-1-specific 
CD8+ T cells, whereas IL-23 has no effect. In conclusion, these results point to a pivotal role of butyrate 
and propionate in modulating CD8+ T cell activation via the inhibition of IL-12 secretion from DCs. These 
findings reveal a novel mechanism whereby bacterial fermentation products may modulate CD8+ T cell 
function with possible implications in anti-cancer immunotherapy.
The gut microbiota has strong influence on the human immune system and health via the production of a vari-
ety of metabolites detectable in host circulation1–3. Through fermentation of dietary poly- and oligosaccharides 
resistant to digestion in the small intestine, the distal gut microbiota can metabolize complex carbohydrates to 
produce small organic acids, the majority of which are comprised of the short chain fatty acids (SCFAs) acetate, 
propionate, and butyrate4. Acetate, propionate and butyrate are found at molar ratios of 60:20:20 in the intes-
tinal tract, reaching peak concentrations in the gut lumen (50–100 mM). Due to their structure they are easily 
absorbed into the portal circulation, through which they reach the bloodstream at much lower concentrations 
than found in the gut lumen5–9. SCFAs affect cells both by the interaction with their specific G protein-coupled 
receptors (GPR)-41, GPR43 and GPR109A and independently of these receptors10–13. Butyrate and, to a lesser 
degree, propionate inhibit histone-deacetylases (HDAC) thereby affecting host gene expression14 and induc-
ing autophagy15. Several evidences highlight the importance and broad role of SCFAs from regulating energy 
homeostasis16 to modification of immune cell function and responses8,9,17,18. We have shown that human 
monocyte-derived dendritic cells (DC) express GPR41 and GPR109A, and that SCFA treatment affect gene 
expression in lipopolysaccharide (LPS)-activated DCs19. In peripheral tissues, DCs are found in an immature 
stage specialized in detecting and capturing antigens through expression of innate pattern recognition receptors. 
When activated by pathogen-associated molecular patterns, immature DCs undergo phenotypic and qualitative 
changes to become mature DCs and migrate from the periphery into the draining lymph nodes where they pres-
ent pathogen-derived peptides to CD4+ and CD8+ T cells20–22. The environment in which the DCs are activated 
1Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. 2Center for 
Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, Denmark. 
Correspondence and requests for materials should be addressed to A.W. (email: awoetmann@sund.ku.dk)
Received: 22 June 2017
Accepted: 20 October 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIenTIfIC REPORTS | 7: 14516  | DOI:10.1038/s41598-017-15099-w
greatly shapes their ability to activate and differentiate T cells20. Cytotoxic CD8+ T cells (CTLs) are pivotal for 
the killing and clearance of virus-infected cells and cancer cells. The generation of antigen-specific memory and 
effector CTLs from naïve CD8+ T cells relies on antigen presentation by DCs23–25 in combination with surface 
expression of co-stimulatory molecules like CD80, CD83, CD86, CD40, OX40-L or ICOS-L21,26. In addition, 
inflammatory cytokines like IL-1, IL-6, and IL-12 produced by the activated DCs and/or macrophages during the 
priming phase provide the necessary signal 3 that further induces cell division and development of CTL effector 
functions27–30. To study the effect of SCFAs on the DC-mediated activation of antigen-specific CTLs, we studied 
MART-1-specific CD8+ T cells co-cultured with MART-1 peptide pulsed autologous HLA-A201+ DCs previously 
treated with SCFAs. We used MART-1 as model antigen since around 0.1% of naive CD8+ T cells are MART-1–
specific and they can be found in HLA-A201+ individuals regardless of prior antigen exposure31,32. We found that 
butyrate and propionate significantly suppressed the activation of MART-1-specific CTLs. In search for mecha-
nism involved in this suppression, we discovered that butyrate and propionate inhibited production of IL-12 and 
IL-23 in the DCs and that the CTL activation could be fully reconstituted by exogenous supplementation of IL-12. 
Our work adds a new dowel to the understanding of the host-microbiota mutualism by revealing that SCFAs can 
dampen CTL activation via their effect on DCs.
Results
Butyrate and propionate inhibit activation of antigen-specific CTLs. To study whether SCFAs 
affect activation of CTLs in T cell-DC co-cultures, we used monocytes isolated from healthy HLA-A0201+ donors 
to generate immature DCs (iDC). The iDCs were either left untreated or were stimulated with LPS for 24 h in 
the absence or presence of sodium acetate, sodium butyrate, or sodium propionate to generate mDC, mDC_A, 
mDC_B, and mDC_P, respectively, as previously described19. After 24 h, the DCs were pulsed with peptides and 
cultured for 10 days with autologous CD8+ T cells.
Subsequently, we analysed the frequency of activated MART-1 specific CTLs as determined by 
IFN-γ+TNF-α−, IFN-γ+TNF-α+-, or IFN-γ−TNF-α+-producing CD8+ T cells. In order to reduce the variability 
among donors, we normalized the measured frequences of each subpopulation to the respective values obtained 
when CD8+ T cells were in co-cultures with mDC. We found that expansion of both the IFN-γ+TNF-α− and 
the IFN-γ+TNF-α+-producing MART-1 specific CD8+ T cells was significantly impaired in mDC_B (P ≤ 0.001 
and P ≤ 0.0001, respectively) and mDC_P co-cultures (P ≤ 0.01 and P ≤ 0.01, respectively) (Fig. 1a and b), 
while the IFN-γ−TNF-α+-producing CD8+ T cells expansion was only significantly impaired in mDC_P 
co-cultures (P ≤ 0.05) (Fig. 1c). In addition, non-normalized values were reported in Supplementary Fig. 1. 
Indeed, analyses of the raw data confirmed the strong inhibition of the expansion of IFN-γ+TNF-α− and 
IFN-γ+TNF-α+-producing CD8+ T cells exerted by mDC_B (P ≤ 0.001 and P ≤ 0.001, respectively), followed by 
mDC_P (P ≤ 0.01 and P ≤ 0.05, respectively), that also has a significant effect on the IFN-γ−TNF-α+-producing 
CD8+ T cells (P ≤ 0.05) (Supplementary Fig. 1a,c). Essentialy similar tendencies were observed when we used a 
peptide from another weak, endogenous antigen (programmed-death ligand 1, PDL1; Supplementary Fig. 2a,b) 
or peptides from two different strong, exogeneous antigens (Epstein Barr- and Cytomegalo-virus, EBV and CMV 
respectively; Supplementary Fig. 2c–f), indicating that the inhibitory effect, primarily exherted by butyrate, on 
DCs ability to prime and activate CD8+ cells was not limited to MART-1 specific CD8+ T cells. Nevertheless, we 
found a strong consistency of CD8+ responses when MART-1 peptide was used, compared to the others. Given 
the low donor variation observed with MART-1 peptide, we decided to use MART-1 as model for further analysis.
To verify that the activated CTLs were actually peptide-specific CTLs, we stained the cells with HLA-A201/
MART-1-tetramers. Expansion of MART-1 specific CTLs was significantly impaired in co-cultures with mDC_B 
(P ≤ 0.05), but not if in co-culture with mDC_P, when compared to mDC as control (Fig. 1d).
To check whether any of the SCFAs could reduce DCs induced CTLs proliferation, we simultaneously stained 
the CD8+ T cells for the proliferation marker Ki67, a nuclear protein that plays a pivotal role in the regulation of 
T cell division33. We found that the levels of Ki67 were similar for all the groups of CD8+ T cells regardless of the 
SCFA used to pretreat the DCs during their maturation (Fig. 1e).
Taken together, these results indicated that the SCFAs, primarily butyrate followed by propionate, inhibit the 
activation and expansion of the antigen-specific CTLs most probably by affecting the antigen-presenting DCs.
Butyrate and propionate impairs up-regulation of co-stimulatory molecules on DCs. To exam-
ine how the individual SCFAs might affect DCs, we stimulated iDCs with LPS in the absence or presence of 
SCFAs and measured the surface expression of CD83, CD80, CD40, CD86, HLA-DR (MHC Class II), HLA-pan 
Class I (MHC Class I) by flow cytometry (Fig. 2a–f). We found a significant inhibition of the expression of the 
co-stimulatory molecules CD83, CD80, and CD40 after butyrate treatment (P ≤ 0.001, P ≤ 0.05, and P ≤ 0.01, 
respectively), and a significant reduction in CD83 and CD80 expression exerted by propionate (P ≤ 0.05, both) 
(Fig. 2a–c). SCFA treatment of mDCs had no effect on either surface expression levels of CD86, HLA-DR or 
HLA-ABC (Fig. 2d–f), or viability (Supplementary Fig. 3).
SCFAs reduce the secretion of IL-6, IL-12, and IL-23 from DCs. As previously shown by our group, 
butyrate and propionate exert a strong immunomodulatory effect on LPS-stimulated DCs. Thus, we previously 
reported that butyrate and propionate-treated mDCs down-regulate LPS-induced IL-6, IL-12B, and chemokine 
genes and protein expression19. Here, we confirm what we have previously shown regarding IL-6 (Fig. 3a). In 
addition we have found that SCFAs affect the secretion of both IL-12p70 and IL-23 (n = 12) (Fig. 3b and c respec-
tively). Indeed, butyrate and propionate strongly inhibit mDCs secretion of IL-12p70 (both P ≤ 0.001) (Fig. 3b) 
and IL-23 (P ≤ 0.01 and P ≤ 0.05, respectively) (Fig. 3c). We have previously shown that acetate had no effect on 
any of the investigated cytokines or chemokines19, but surprisingly we see a reduction of IL-12p70 secretion by 
mDCs after acetate treatments (P ≤ 0.05) (Fig. 3b).
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Addition of exogenous IL-12 rescues expansion of CTLs in co-cultures with SCFA-treated DCs. 
The inhibition of IL-6, IL-12p70 and IL-23 release from mature DCs and their subsequent lack in the surrounding 
niche led us to explore the presumable necessity to replace signal 3 for a CTLs activation. To this purpose we per-
formed the same co-culture experiments and ICS analysis in parallel, as previously reported above, but now sup-
plementing the culture media with each of the individual cytokines. As shown in Figs 4 and 5a, we observed that 
the exogenous IL-12 media supplementation was able to rescue the number of the IFN-γ+ TNF-α− -producing 
Figure 1. Butyrate and propionate inhibit activation of antigen-specific CTLs. (a) Chart represents the 
percentages of activated IFN-γ+ TNF-α− and (b) IFN-γ+ TNF-α+- and (c) IFN-γ− TNF-α+-producing CD8+ 
T cells after 10 days of co-culture with MART-1 pulsed iDCs, mDCs, mDC_A, mDC_B, and mDC_P. Values 
have been normalized to those CD8+ T cells in co-culture with untreated mDCs that has defined the activation 
threshold for each individual donor (n = 12). Shown are the percentages of (d) MART-1-specific CD8+ T 
cells and (e) KI67+ CD8+ T cells in co-cultured with DCs treated as previously mentioned (n = 4). Wilcoxon 
matched-pairs signed rank tests were run for the a–c analysis, and Mann-Whitney tests for d–e. **P ≤ 0.01, 
***P ≤ 0.001.
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CD8+ T cells population with butyrate- and propionate-treated mDC co-cultures (Fig. 5a, both P ≤ 0.05). The 
same has been observed in the raw data reported in Supplementary Fig. 5a, where it is also possible to appreciate 
the effect of IL-12 in significantly restoring the IFN-γ+ TNF-α−-producing CD8+ T cells in all three SCFA-treated 
mDC co-cultures (Supplementary Fig. 5a, all P ≤ 0.05).
Regarding the IFN-γ+ TNF-α+-producing CD8+ T cells population, IL-12 seemed to exert the same effect 
only on those ones in co-culture with butyrate-treated mDCs (n = 5) (Fig. 4 and 5b, P ≤ 0.05). This unfortunately 
can not be appreciated in the raw data reported in Supplementary Fig. 5b. About the IFN-γ−TNF-α+-producing 
CD8+ T cells population, IL-12 seemed to rescue them only if in co-cultures with propionate-treated mDC (Figs 4 
and 5c, P ≤ 0.05). On the other hand, neither the addition of IL-23 (n = 3) (Figs 4 and 5d–f) nor of IL-6 (n = 2) 
(Supplementary Fig. 4) was capable to restore the CTLs functionality, indicating that the butyrate and propionate 
affect the CD8+ T cell mainly via the inhibition on DCs production of IL-12. Furthermore, IL-12 reintroduction 
into the culture can sufficiently drive back the CTLs functionality to a normal level, overcoming the lack of 
costimulatory molecules. It has previously been shown that IL-12, but not IL-23, significantly augments IFN-γ 
production by CD8+ T cells34 and that IL-12 provides the essential signal 3 for the naïve CD8+ T cells priming 
and activation by DCs28.
Figure 2. Butyrate and propionate impairs up-regulation of co-stimulatory molecules on DCs. Charts represent 
the mean fluorescence intensity (MFI) values of each donor’s sample. Shown are the averages ± standard 
deviations (SD) (a,b,f n = 14; e n = 12; c,b n = 8); Two-tailed paired Student’s t-tests, *P < 0.05, **P ≤ 0.01, 
***P ≤ 0.001.
Figure 3. SCFAs reduce the secretion of IL-6, IL-12, and IL-23 from DCs. Shown are the averages ± standard 
deviations (SD) of (a) IL-6, (b) IL-12p40, (c) and IL-23 cytokines released into the media by monocyte-derived 
DCs and detected by ELISA from n = 12 donors. Two-tailed paired Student’s t-tests, *P < 0.05, **P ≤ 0.01, 
***P ≤ 0.001.
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Taken together, our results provide a new insight to how SCFA affect DCs ability to prime CTLs and induce 
their cytokines production, and shead new light to the understanding of the exclusive and strong effect of IL-12.
Discussion
The microbiome plays an important role in health and disease1,2,35 and a shift in balance between a healthy and 
dysbiotic microbiome leads to pathologic and metabolic conditions including obesity, colon cancer, IBD, and 
allergic asthma17,36–39. Short-chain fatty acids, such as acetate, butyrate and propionate, are end-products of 
microbial fermentation of macronutrients by the human gut microbiota that distribute systemically via lymphat-
ics to the blood5,6. It is well known that SCFAs show immunomodulatory abilities, exerting a specific effect on 
distinct human and murine immune cells3,13,19,40,41. Antigen-presenting cells, such as DCs, couple innate recogni-
tion to adaptive immunity and, thus, the signals that convert resting antigen-presenting cells into immunogenic, 
or tolerogenic, are crucial. In fact, a successful priming of the adaptive immune responses is directly dependent 
on the innate signals and stimuli used to activate the innate component. SCFAs have shown to exert a important 
role in directly shaping the naive CD4+ T cells polarization, either directly or via their effect on DCs40,42. In this 
study we tested a hypothesis that SCFA, via their effect on DCs, can also impact the priming of CD8+ T cell, and 
thus their responses.
Impairing DCs maturation or any of the activating signals leads to a reduced functionality of the effector 
cells of the adaptive immune system including CD8+ T cells43. DCs deliver the required signals to activate naïve 
CD8+ T cells, and without these signals the adaptive immune responses would not be elicited. DCs ability to 
stimulate naïve T cells strictly depends on their state of maturation20. Thus, mature DCs will present several key 
activating ligands or secreted factors to naïve CD8+ T cells during priming such as peptide-MHC complexes 
(signal 1), costimulatory molecules (signal 2), and cytokines (signal 3)30. Generally, expression of costimulatory 
molecules on DC is essentially involved in controlling T cell differentiation and the resulting immune responses. 
We observed that both butyrate and propionate down-regulate the LPS-induced co-stimulatory molecules CD83, 
CD80, and CD40 presumably inhibiting their ability to correctly interact with CD8+ T cells during the priming 
and activation steps. MHC class I/II expression is pivotal for activation of T cells providing the first signal needed 
for the activation of a naïve T cells. We observed no effect of SCFA on MHC class I or II expression, indicating 
that SCFA do not compromise the antigens presentation via MHC molecules, thus a correct interaction between 
TCR and MHC can still be established. CD80 and CD86 expression on DCs probably constitute the most impor-
tant costimulatory molecules in T cell activation. Signaling through binding partner CD28 on T cells confers 
optimal mRNA stabilization and production of IL-2, a factor that promotes expansion and survival of primary 
Figure 4. Gating strategy used for flow cytometry analysis. FACS plots are shown as representative example 
of the gating strategy used in each experiment, combined with the plots showing the comparison of IFN-γ and 
TNF-α cytokine production by CD8+ T cells after supplementing the media with eiter IL-12 or IL-23.
www.nature.com/scientificreports/
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T cells44. Human iDC constitutively express intermediate amounts of CD86 and lack CD80, while mature DCs 
express higher amount of both45. While the down regulation of CD80 may compensate by the unaffected CD86 
(considering their shared ligand), the lack of CD40 and CD83 might not. Indeed, it is known that the CD40 binds 
CD40L on T cells and its pathway regulates cellular and humoral immunity and plays an important role in T cell 
priming and differentiation46. Indeed, CD40 ligation on DCs increases expression of costimulatory, adhesion and 
MHC molecules and promotes the production of T cell stimulatory cytokines such as IL-1247,48. CD83 functions 
as an enhancer during the stimulation of T cells, and induces clear changes in cytokine expression during T cell 
Figure 5. Addition of exogenous IL-12 rescues the activity of CTLs in co-cultures with SCFA-treated DCs. 
Charts represent the percentages of activated IFN-γ+ TNF-α−, IFN-γ+ TNF-α+, and IFN-γ− TNF-α+-
producing CD8+ T cells after 10 days of co-culture with MART-1 pulsed iDCs, mDCs, mDC_A, mDC_B, and 
mDC_P with and without (a–c) IL-12 (donors n = 5), (d–f) IL-23 (n = 3) supplementation into the media. 
Values have been normalized to those CD8+ T cells in co-culture with untreated mDC that has defined the 
activation threshold for each individual donor. Multiple t-tests with Holm-Sidak as correction method, 
*P < 0.05.
www.nature.com/scientificreports/
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priming49. Furthermore, the engagement of CD83 ligand on human T cells preferentially enriches, and signifi-
cantly amplifies, the number of antigen-specific CD8+ T cells, thus by affecting its expression it results in com-
promised T cell proliferation50–52. We have observed the same tendency of butyrate-or propionate-treated mDC 
to decrease the numbers of IFN-γ+TNF-α− and the IFN-γ+TNF-α+-producing CD8+ T cells when in co-culture 
in all experiments regardless of the peptides used (Fig. 1 and Supplementary Fig. 2); nevertheless we found a 
strong consistency of CD8+ T cell responses when MART-1 peptide was used compared to the others. CD8+ T 
cell responses to different antigen-derived peptides depend greatly on their affinity towards MHC class I, and 
to prior exposure to infections (EBV and CMV). This gives very individual responses to the different peptides, 
and result in a large donor variation. Taken together, this led us to consider MART-1 the most reliable peptide to 
use as a model for further analysis. Overall, we observed that both butyrate- and propionate-treated mDC were 
significantly impaired in priming/inducing the IFN-γ+ TNF-α−-producing-, IFN-γ+ TNF-α+-producing CD8+ 
T cells, and only propionate to affect the IFN-γ− TNF-α+-producing CD8+ T cells, while the peptide-specificity 
and the proliferation of the CD8+ T cells were not impaired.
Taken together, our results indicate the the effects of butyrate and propionate on DCs ability to activate CD8+ 
T cells are not merely cause by the lack of CD40, CD80, and CD83 on the DCs surface (that leads to a reduction of 
survival cytokines release by the activated T cells e.g. IL-2, IL-5) but to a higher degree to the impairment of signal 
3, that is usually represented by the cytokines produced by the antigen presenting cells.
We have confirmed, what we have previously shown, that butyrate significantly reduce IL-6 expression 
and release by human monocyte-derived DCs19. In addition, we here show that both butyrate and propionate 
down-regulates the LPS-induced cytokine release of IL-12p70 and IL-23; cytokines that polarize naïve CD4+ T 
cells towards Th1 and Th17, thus eliciting pro-inflammatory properties as recently shown by Haghikia et al.42. To 
investigate whether reduced expression of cytokines from SCFA-treated DCs were responsible for the observed 
CD8+ T cells activation, we performed co-culture experiments with supplemented cytokines. Indeed, when sup-
plementing the co-culture media with IL-12 the IFN-γ+ TNF-α−-producing CD8+ T cells were restored, and even 
enhanced, in both butyrate- and propionate-mDC co-cultures; while the IFN-γ+ TNF-α+-producing CD8+ T cells 
population was just sufficiently restored in butyrate-mDC co-cultures, and the IFN-γ− TNF-α+-producing CD8+ 
T cells population was just rescued in the propionate-mDC co-cultures. We did not observe the same effect with 
either IL-23 or IL-6 supplementation, leading to support the important role that IL-12 plays in the CD8+ T cells 
activation and in initiating and supporting the IFN-γ and TNF-α production. Indeed, as previously shown28–30, 
IL-12 provides a third signal exclusively to naive CD8+ T cells, and the response to IL-12 as well as to peptide 
antigens depends on co-stimulation. IL-12 is known to increase CD8+ T cell cytolysis, survival, proliferation, and 
at the same time influence the ability of the cells to migrate to inflammatory loci. On the other hand, IL-23 has 
the ability to stimulate the production of IL-17 by CD4+ T cells, important for immune reactions against extra-
cellular pathogens27, but its role in the activation of naïve CD8+ T cells is still poorly understood. IL-12 and IL-23 
share the p40 subunit, but most probably due to their specific and different receptors, they activate distinct sets 
of downstream transcriptor factors, thus that IL-12 leads to IFN-γ production while IL-23 does not induce nei-
ther IFN-γ nor TNF-α. In our study, we show that SCFAs affect co-stimulatory molecules surface expression on 
DCs, as well as cytokine production of these APCs and ability to prime CD8+ T cells. On the other hand SCFAs 
rather impair the CTLs IFN-γ+ and TNF-α+ production and peptide-specificity but have no effect on prolifer-
ation. Thus, we assumed that it could be due to the down-regulation of CD40, CD80 and particularly of CD83 
expression (that indirectly leads to a reduced cytokines release by T cells as already shown by Prechtel et al.49), 
but also due to the impairment of signal 3 by treated DCs.
We here propose that SCFA, produced by our commensals, support a more tolerogenic activation of the innate 
immune system’s component rather than a pro-inflammatory stimulation. This could be seen as a strategic way to 
avoid a strong immune response towards their own producers, damping a potential cytotoxic activity in the gut 
that could impair the gut mucosa integrity, while not affecting the immune system’s ability to defeat a potential 
invading pathogen.
Materials and Methods
Peripheral blood mononuclear cells (PBMC) isolation. PBMCs were isolated from buffy coats 
obtained from anonymous healthy blood donors by Ficoll-Hypaque density gradient centrifugation. Before pro-
cessing, all the buffy coats were screened for HLA-A0201 positivity using HLA-A2 (BD, BB7.2) antibody and only 
those positive were chosen for further analysis. Written informed consent was obtained from blood donors at 
the Department of Clinical Immunology, University Hospital Rigshospitalet, Copenhagen and used without the 
possibility to identify case specific information: The ethical committee, Region H, Capital Region of Denmark, 
approved the use of these buffy coats for research that was carried out in accordance with the approved guidelines.
Culture of monocyte-derived DC and autologous CD8+ T cells. CD14+ monocytes and CD8+ T cells 
were isolated from PBMCs by positive selection using magnetic beads in accordance with the manufacturer’s 
instructions (Miltenyi Biotec, Germany). Monocytes were cultured at 37 °C in 5% CO2 in media supplemented 
with 10% fetal bovine serum (FBS, ThermoFisher) GM-CSF and IL-4 (both 50 ng/ml; PeproTech, Rocky Hill, NJ) 
for 7 days to generate iDC and mDC, the last obtained after LPS (100 ng/ml, E. coli 055:B5, Sigma-Aldrich) stimu-
lation for the last 24 h in parallel with a single addition of 1 mM to acetate, propionate or butyrate (Sigma-Aldrich) 
leading to the following groups of treatments: sodium acetate (mDC_A), sodium butyrate (mDC_B), sodium 
propionate (mDC_P).
DC-CD8+ T cells co-culture. After 7 days of culture, iDCs, mDCs, mDC_A, mDC_B, and mDC_P were 
harvested, the supernatants stored, and cells were washed and resuspended in X-VIVO 15 (Gibco, Lonza), 
and subsequently pulsed with 1 mM MART-1 peptide (ELAGIGILTV), EBV BLMF1 peptide (GLCTLVAML), 
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PDL101 peptide (LLNAFTVTV), or CMV pp65 peptide (NLVPMVATV) (all by KJ Ross Petersen Aps, 
Copenhagen, Denmark) at 37◦C for 2 h. Hereafter DCs (0.5 × 105) were washed twice and incubated in 48-wells 
culture plates together with autologous CD8+ T cells (0.5 × 106). The general informations and throubleshooting 
advices were taken from Wolfl et al.53. For each condition (iDCs, mDCs, mDC_A, mDC_B, mDC_P) were plated 
3–5 co-culture replica in order to be able to exclude possible technical errors. At day 3 and 6, half of the medium 
was refreshed with new containing rIL-2 (50 U/ml, Novartis) and rIL-7 (10 ng/ml, Peprotech, Rocky Hill, NJ). For 
experiments with supplement of exogenous rIL-12, rIL-6 and rIL-23 (10 ng/ml; Peprotech, Rocky Hill, NJ) were 
added together with the medium refreshment at day 3 and 6 of the co-culture.
Flow cytometry analysis. Cells were stained at 4 °C for 30 min in FACS buffer (1%BSA, 0.01% sodium 
azide, PBS), washed, resuspended in the same buffer. Isotype-matched antibodies were used to define and 
exclude the background staining. 7-AAD (BD Pharmigen) (for the DCs phenotype), or LIVE/DEAD® Fixable 
Far Near-IR stain (Invitrogen) (for the intracellular stainings) was used to exclude dead cells. DCs analysis was 
conducted with anti-human: HLA-pan class I (clone W6/32), HLA-DR (clone L243), anti-human CD83 (clone 
HB15e), CD86 (clone 2331 FUN1), CD40 (clone 5C3), CD80 (clone L307.4), all purchased at BD Bioscience.
Functional analysis of CD8+ T cell from co-culture experiments were preformed via intracellular cytokine 
stainings at day nine. CD8+ T cells were harvested, washed and plated in a 96-wells round plates, and re-stimulated 
with MART-1 peptide for 4 h with the addition of GolgiPlug (Brefeldin A, BD) for the last 3 h. Anti-human CD3 
(BD, clone SK7), CD8 (BD, clone RPA-T8) and LIVE/DEAD® Fixable Far Near-IR stain (Invitrogen) were used 
for gating live CD3+CD8+ T cells, followed by the fixation and the permeabilization with the Transcription factor 
Staining Buffer Set (eBioscience, 00–5523) for the detection analysis of intracellular cytokines production by 
anti-human IFN-γ (clone B27) and TNF-α (MAb11) (both BD Bioscience). For analysis of antigen-specificity, 
CD8+ T cells stained with PE-conjugated peptide-HLA-A2 MHC-tetramer (30 nM, immunAware, Denmark) for 
30 min at 37 °C followed by surface markers staining of CD8 and CD3 for 30 min at 4 °C. Data acquisition and 
flow cytometric analysis were done on by LSRFortessa™ (BD Bioscience) at the CFFC (Core Facility for Flow 
Cytometry, Faculty of Health and Medical Sciences, University of Copenhagen). All data analysis was performed 
with FlowJo v7.0 (Treestar, Ashland, OR).
ELISA assay. Supernatants from DC maturation cultures were collected and frozen at 80 °C during DC har-
vest. IL-6, IL-12p70, and IL-23 production was measured in the supernatants of DC by ELISA following the 
manufacturer’s instructions (R&D Systems, Inc.).
Statistical analysis. Two-tailed paired Student’s t-tests were used with a significance level of 0.05. Before 
each test the Gaussian distribution of the samples data was checked though D’Agostino-Pearson normality test, 
if the test was not passed a non-parametric test was performed. All the analysis were made by GraphPad Prism 
6.0 and the nomenclature for the P values is the following: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
Each donor has been considered as independent experiment and all the flow cytometry data were performed 
with 3 up 5 technical replicates for each condition.
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